In a significant discovery, a team of researchers led by an Indian-American has found that a single gene dysfunction in mice results in developing fasting hypoglycemia, one of the major symptoms of Type 2 diabetes.

The discovery by researchers, led by Prof. Bellur S Prabhakar, focused on a gene MADD for the study and may enable a new potential treatment for diabetes patients.

If MADD is not functioning properly, insulin is not released into the bloodstream to regulate blood sugar levels, said Prabhakar, professor and head of microbiology and immunology at University of Illinois at Chicago.

In previous work, Prabhakar isolated several genes from human beta cells, including MADD, which is also involved in certain cancers. Small genetic variations found among thousands of human subjects revealed that a mutation in MADD was strongly associated with Type 2 diabetes in Europeans and Han Chinese.

People with this mutation had high blood glucose and problems of insulin secretion - the "hallmarks of type 2 diabetes", Prabhakar said.

But it was unclear how the mutation was causing the symptoms, or whether it caused them on its own or in concert with other genes associated with Type 2 diabetes.

To study the role of MADD in diabetes, Prabhakar and his colleagues developed a mouse model in which the MADD gene was deleted from the insulin-producing beta cells. All such mice had elevated blood glucose levels, which the researchers found was due to insufficient release of insulin.

"We didn't see any insulin resistance in their cells, but it was clear that the beta cells were not functioning properly," Prabhakar said.

Examination of the beta cells revealed that they were packed with insulin. "The cells were producing plenty of insulin, they just weren't secreting it," he said.

Prabhakar said that the work shows that Type 2 diabetes can be directly caused by the loss of a properly functioning MADD gene alone.

"Without the gene, insulin can't leave the beta cells, and blood glucose levels are chronically high," he said.

In the future, the researchers plan to look into effects of a drug that allows for the secretion of insulin in MADD-deficient beta cells.

"If this drug works to reverse the deficits associated with a defective MADD gene in the beta cells of our model mice, it may have potential for treating people with this mutation who have an insulin-secretion defect and/or type 2 diabetes," he said.

Type 2 diabetes affects roughly 8 per cent of Americans and over 366 million people worldwide. It can cause serious complications, including cardiovascular disease, kidney failure, loss of limbs and blindness.

Eating a diet packed with lentils can dramatically lower blood pressure levels, a new study has found.

The study from the University of Manitoba in Canada found that adding lentils to the diet can effectively block the increase in blood pressure that occurs with age.

The research, conducted on rats, also found that eating lentils can reverse the changes that occur in blood vessels as a result of high blood pressure.

"These are amazing results, since they provide a non-pharmacological way of treating diseases associated with blood vessel dysfunction," said Dr Peter Zahradka, one of the lead investigators for the study.

The findings are a continuation of two studies published earlier this year, 'the Daily Express' reported.

One of these was a clinical trial which revealed how eating legumes - specifically a mixture of beans, peas, lentils and chickpeas - could improve blood flow to the legs of people with peripheral artery disease.

The second showed that lentils were effective in blocking high blood pressure.

"The most notable finding of the latest study was the fact that lentils could alter the physical properties of blood vessels so that they resembled the vessels found in healthy animals," Zahradka said.

Scientists seeking a cure for AIDS say they have been inspired, not crushed, by a major setback in which two HIV positive patients believed to have been cured found the virus re-invading their bodies once more.

True, the news hit hard last month that the so-called "Boston patients" - two men who received bone marrow transplants that appeared to rid them completely of the AIDS-causing virus - had relapsed and gone back onto antiretroviral treatment.

But experts say the disappointment could lay the basis for important leaps forward in the search for a cure.

"It's a setback for the patients, of course, but an advance for the field because the field has now gained a lot more knowledge," said Steven Deeks, a professor and HIV expert at the University of California, San Francisco.

He and other experts say the primary practical message is that current tests designed to detect even very low levels of HIV present in the body are simply not sensitive enough.

As well as having the human immunodeficiency virus (HIV), the Boston patients both also had a type of blood cancer called lymphoma, for which they were treated using bone marrow transplants - one man in 2008 and the other in 2010.

They continued taking the antiretroviral AIDS drugs, but eight months after each patient's transplant, doctors found they could not detect any sign of HIV in their blood.

In the early part of 2013, both patients decided to stop taking their AIDS drugs and both appeared to remain HIV-free - prompting their doctors, Timothy Henrich and Daniel Kuritzkes from Boston's Brigham and Women's Hospital, to announce at a conference in July that they may have been cured.

Yet in December came news that one of the men had begun to show signs of an HIV rebound by August, while the second patient had a relapse in November.

Henrich said the virus' comeback underlined how ingenious HIV can be in finding hiding places in the body to evade attack efforts by the immune system and by drug treatment.

"Through this research we have discovered the HIV reservoir is deeper and more persistent than previously known and that our current standards of probing for HIV may not be sufficient," he said, adding that both patients were "currently in good health" and back on antiretroviral therapy.

INSPIRATION

Barely a decade ago, few HIV scientists would have dared put the words HIV and cure in the same sentence. Yet some intriguing and inspiring cases in recent years mean many now believe it is just a question of time before a cure is found.

First was the now famous case of Timothy Ray Brown, the so-called "Berlin patient," whose HIV was eradicated by a complex treatment for leukemia in 2007 involving the destruction of his immune system and a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection.

Such an elaborate, expensive and life-threatening procedure could never be used as a broad-spectrum approach for the world's 34 million HIV patients. But the results in Brown focused scientific attention on a genetic mutation known as 'CCR5 delta 32' as a target for possible gene therapy treatment.

Then last March, French scientists who followed 14 HIV-positive people known as the "Visconti patients", who were treated very swiftly with HIV drugs but then stopped treatment, said that even after seven years off therapy, they were still showing no signs of the virus rebounding.

That announcement came only weeks after news of the "functional cure" of an HIV-positive baby in Mississippi who received antiretroviral treatment for 18 months from the day she was born. By the time she was two this appeared to have stopped the virus replicating and spreading.

A "functional cure" is when HIV is reduced to such low levels that it is kept at bay even without treatment, though the virus can still be detected in the body.

Sharon Lewin, an HIV expert at Monash University in Australia, said all these developments, as well as the setback suffered by the Boston patients, inspired scientists to investigate many different approaches in the search for a cure.

"We've learnt many things here - and one of the most important is that a tiny, tiny amount of virus can get the whole thing going again," she said. "It's a clear message that we need better ways to pick up the virus."

Scientists are now more convinced than ever that a two-pronged approach which aims to firmly suppress the virus while bolstering the immune system provides the best way forward.

"We need to attack in two ways - reduce the virus to very low levels and also to boost the immune response. We can't do one without the other," said Lewin.

"So we still have to think of other creative ways to control HIV. And it's still early days... before we can say which approach is likely to be the winner."

Researchers have suggested that smokers should follow a New Year's quit with a weekly recommitment to quit that takes advantage of natural weekly cycles.

In a 2013 study published in JAMA Internal Medicine, researchers from San Diego State University, the Santa Fe Institute, The Monday Campaigns and the Johns Hopkins Bloomberg School of Public Health monitored global Google search query logs from 2008 to 2012 in English, French, Chinese, Portuguese, Russian, and Spanish for searches related to quitting, such as "help quit smoking," to examine weekly patterns in smoking cessation contemplations for the first time.

The study found that people search about quitting smoking more often early in the week, with the highest query volumes on Mondays.

Besides catching smokers' attention on Mondays, weekly cues can help people stay on track with their quit attempts. Since it takes an average of seven to 10 quit attempts to succeed, encouraging people to requit or recommit to their quit attempt once a week can reduce the overall time it takes to quit for good.

Joanna Cohen, a co-author of the Google study and director of the Johns Hopkins Bloomberg School of Public Health Institute for Global Tobacco Control, believes "campaigns for people to quit may benefit from shifting to weekly cues to increase the number of quit attempts participants make each year." In other words, quitters can use Monday as a weekly re-set to make another quit attempt if they slip up.

Morgan Johnson, director of programs and research at the Monday Campaigns and another co-author of the Google paper, said that the surge in quitting contemplations on Monday can be used to provide social support for quitters, an important factor in long-term success.

The study has been published in the Journal of Clinical Psychology.